Israeli ADHD-Drug Maker Alcobra Seeks $27 Million in IPO

Alcobra Pharma, an Israeli company developing an oral medicine with reduced side effects to treat attention deficit hyperactivity disorder, filed to raise as much as $27.3 million in a Nasdaq initial public offering.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.